Stocktoria
Upstream Bio, Inc. UPB
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-10-11
Upstream Bio, Inc. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $2.9M | $2.4M | $2.4M |
| R&D expense | $136.8M | $63.0M | $31.8M |
| Operating income | -$160.4M | -$77.8M | -$40.1M |
| Income tax | $0 | $0 | $0 |
| Net income | -$143.4M | -$62.8M | -$20.5M |
| EPS (diluted) | $-2.66 | $-5.58 | $-12.95 |
| Operating cash flow | -$133.3M | -$59.2M | -$37.9M |
| Free cash flow | -$133.4M | -$59.7M | -$38.1M |
| Cash & equivalents | $101.6M | $325.9M | $25.8M |
| Total assets | $353.8M | $481.7M | $117.2M |
| Total liabilities | $14.0M | $11.9M | $9.4M |
| Shareholders' equity | $339.8M | $469.9M | -$123.1M |
Growth · year-over-year · Revenue CAGR 9.5%
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | +20.4% | -0.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.